This company has very interesting products in development. They
have a library of Chinese medicine extracts which they are screening
for treatment of diseases from AIDS to cancer. If you think this
sounds somewhat farfetched, consider that they are collaborating with
the National Cancer Institute (Bethesda, MD) - their science is sound.
Their lead product, PN355, a tyrosine kinase inhibitor, interferes
with intracellular signalling within T-cells, and is in Phase I
trials for combatting HIV-1. They are also collaborating with the
National Cancer Insitute to develop PN355 and related compounds for
treating cancer.
The stock is low now, about 1 1/2. Consider that the 52-week high was
8, and the low was 15/16. The stock made a recent run into the mid
2's, and I think it may make another run soon. I have heard from
my broker that the manager of the Health Sciences Fund bought a lot
of this stock last week at 1 7/8. At 1 1/2, I think it is a good
buy. Of course, it is very risky, but if any positive Phase II results
are announced, the price could skyrocket. |
